CURRENTLY in the red, copper wires and rods manufacturer Ta Win Holdings Bhd is counting on its acquisition of a 32.5% associate stake in Royce Pharma Manufacturing Sdn Bhd to give it a shot in the arm. Even so, the pharmaceuticals business is unchartered waters for Ta Win, and Royce Pharma is loss-making.
The latest available financials show that Royce Pharma made a net loss of RM682,653 on revenue of RM24.13 million for the financial year ended Dec 31, 2018. Its retained losses stood at RM2.6 million.
Ta Win reported a wider net loss of RM2.75 million in the first quarter of its financial year ending June 30, 2021 (1QFY2021), from a net loss of RM2.08 million in 1QFY2020, owing to the impact from the Movement Control Order. However, revenue for the quarter increased 27% year on year to RM85 million.
SURGE IN POPULARITY AMONG MUSLIM WOMEN TO INFLUENCE GLOBAL HALAL COSMETICS MARKET GROWTH
comunicati.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from comunicati.net Daily Mail and Mail on Sunday newspapers.
Halal cosmetics market- Segmented By Product Type, End-Use Type and Geography – Growth, Trends & Forecast, 2026
comunicati.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from comunicati.net Daily Mail and Mail on Sunday newspapers.
KUALA LUMPUR (Dec 14): Ta Win Holdings Bhd will be acquiring a 32.5% stake in pharmaceutical company Royce Pharma Manufacturing Sdn Bhd for RM20.85 million.
In a bourse filing, the group said its wholly-owned subsidiary Ta Win Copper Biohealth Sdn Bhd (TWC Biohealth) inked a share sale agreement with Poly Lab Sdn Bhd for the acquisition of a 22.8% or 2.74 million share stake in Royce Pharma for RM14.64 million.
At the same time, it signed a subscription agreement with Royce Pharma and the latter’s shareholders Poly Lab and Jelita Serbaneka Sdn Bhd for the subscription of 1.16 million new shares, which represent 9.8% of Royce Pharma’s enlarged share capital, at RM6.21 million.